Fintel on MSN14h
Baird Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Outperform Recommendation
Fintel reports that on February 4, 2025, Baird initiated coverage of Catalyst Pharmaceuticals (NasdaqCM:CPRX) with a ...
Baird starts Catalyst Pharma with Outperform, $28 target
Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target ...
Catalyst Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Joel Beatty last night initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Outperform rating and $28 price target ...